Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021011496 - IMMUNOTHERAPEUTIC CONSTRUCTS AND METHODS OF THEIR USE

Publication Number WO/2021/011496
Publication Date 21.01.2021
International Application No. PCT/US2020/041844
International Filing Date 13.07.2020
IPC
A61K 39/39 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 47/68 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/69 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
69the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
CPC
A61K 39/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/69
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
69the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Applicants
  • OREGON HEALTH & SCIENCE UNIVERSITY [US]/[US]
  • PDX PHARMACEUTICALS, INC. [US]/[US]
Inventors
  • YANTASEE, Wassana
  • NGAMCHERDTRAKUL, Worapol
  • LUND, Amanda
  • REDA, Moataz
Agents
  • HARDING, Tanya M.
Priority Data
62/873,76212.07.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) IMMUNOTHERAPEUTIC CONSTRUCTS AND METHODS OF THEIR USE
(FR) CONSTRUCTIONS IMMUNOTHÉRAPEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION
Abstract
(EN)
Disclosed herein are immunotherapeutic constructs comprising a delivery particle, at least one adjuvant, and one or more therapeutic agents/compounds that cause antigen release and/or modulate immunosuppressive tumor microenvironment. These immunotherapeutic constructs create adaptive immunity or anti-cancer immune response(s) that can be used, for instance, to prevent and treat broad types of cancer. Further disclosed are uses of the immunotherapeutic constructs, including to prevent and treat cancer in humans and animals.
(FR)
L'invention concerne des constructions immunothérapeutiques comprenant une particule d'administration, au moins un adjuvant, et un ou plusieurs agents/composés thérapeutiques qui entraînent la libération d'antigène et/ou modulent un microenvironnement tumoral immunosuppresseur. Ces constructions immunothérapeutiques créent une immunité adaptative ou une/des réponse(s) immunitaire(s) anticancéreuse(s) qui peut/peuvent être utilisée(s), par exemple, pour prévenir et traiter des types larges de cancer. L'invention concerne en outre des utilisations des constructions immunothérapeutiques, notamment pour prévenir et traiter le cancer chez l'homme et l'animal.
Latest bibliographic data on file with the International Bureau